Home » Stocks » Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. (RTTR)

May 26, 2020 - RTTR merged into QLGN
Stock Price: $0.448 USD 0.000 (0.00%)
Updated May 22, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 20.68M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 1.85M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day May 22, 2020
Last Price $0.448
Previous Close $0.448
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.440 - 0.540
Day's Volume 17,888,966
52-Week Range 0.150 - 1.270

More Stats

Market Cap 20.68M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 1.85M
Float 46.01M
EPS (basic) n/a
EPS (diluted) -0.44
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 902,896
Short Ratio 0.06
Short % of Float 3.06%
Beta -0.43
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.33
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share 0.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -66.16%
ROE -144.15%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$175.00*
Low
175
Current: $0.448
High
175
Target: 175.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Ritter Pharmaceuticals, Inc.
Country United States
Employees 5
CEO Andrew J. Ritter

Stock Information

Ticker Symbol RTTR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RTTR
IPO Date June 24, 2015

Description

Ritter Pharmaceuticals, Inc. develops and sells therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases. Its lead product candidate is RP-G28, an orally administered galacto-oligosaccharide that is in Phase III clinical trials for the treatment of lactose intolerance. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.